Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2003
09/16/2003US6620382 Method and compositions for treatment of cancers
09/16/2003CA2249009C Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
09/16/2003CA2182183C Treatment of ovarian estrogen dependent conditions
09/16/2003CA2145985C Vascular endothelial cell growth factor antagonists
09/16/2003CA2102782C 2-fluoro-2-substituted adeninyl arabinosides as anti-cancer agents
09/16/2003CA2081343C Therapeutic agents for the treatment of multidrug resistance to cancers
09/12/2003WO2003075015A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
09/12/2003WO2003074736A1 Diagnostics and remedies for malignant brain tumor
09/12/2003WO2003074712A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof
09/12/2003WO2003074711A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
09/12/2003WO2003074695A1 Sumo inhibitors
09/12/2003WO2003074654A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/12/2003WO2003074569A2 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003WO2003074568A1 Individualized anti-cancer antibodies
09/12/2003WO2003074567A2 Internalizing anti-cd74 antibodies and methods of use
09/12/2003WO2003074565A2 Peptides for use in antitumor immunotherapy
09/12/2003WO2003074564A1 Novel hemepeptide
09/12/2003WO2003074547A2 Biologically active complex comprising alpha-lcatalbumin or a variant thereof, and a cofactor
09/12/2003WO2003074529A2 iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
09/12/2003WO2003074527A1 Crystalline polymorphic form of irinotecan hydrochloride
09/12/2003WO2003074524A2 Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs
09/12/2003WO2003074516A1 Phthalimide carboxylic acid derivatives
09/12/2003WO2003074515A1 Diamino-pyrimidines and their use as angiogenesis inhibitors
09/12/2003WO2003074512A1 Isoquinoline derivatives
09/12/2003WO2003074508A1 Compounds and methods of treating cell proliferative diseases
09/12/2003WO2003074490A1 9-aminoacridine derivatives and process for the preparation thereof
09/12/2003WO2003074489A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
09/12/2003WO2003074483A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
09/12/2003WO2003074479A1 Semicarbazide derivatives and their use as antithrombotics
09/12/2003WO2003074098A1 Modified phosphocalcic compound, injectable composition containing same
09/12/2003WO2003074089A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
09/12/2003WO2003074083A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells
09/12/2003WO2003074082A1 Formulations and methods of using nitric oxide mimetics in cancer treatment
09/12/2003WO2003074079A1 Solidified tissue immunological adjuvant
09/12/2003WO2003074078A2 Cg3842 homologous proteins involved in the regulation of energy homeostasis
09/12/2003WO2003074073A2 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
09/12/2003WO2003074062A2 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
09/12/2003WO2003074060A2 Dna demethylase antisense and chemotherapy combination
09/12/2003WO2003074053A1 Use of epothilones in the treatment of brain diseases associated with proliferative processes
09/12/2003WO2003074049A1 Antitumor agents
09/12/2003WO2003074045A1 Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
09/12/2003WO2003074027A2 Self emulsifying drug delivery systems for poorly soluble drugs
09/12/2003WO2003074008A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003WO2003073999A2 Pini-modulating compounds and methods of use thereof
09/12/2003WO2003073998A2 Local production and/or delivery of anti-cancer agents by stromal cell precursors
09/12/2003WO2003073989A2 Nucleoside 5'-monophosphate mimics and their prodrugs
09/12/2003WO2003073986A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003WO2003073918A2 Prevention of recurrence and metastasis of cancer
09/12/2003WO2003073841A2 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
09/12/2003WO2003073828A2 Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
09/12/2003WO2003073821A2 Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
09/12/2003WO2003051828A3 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
09/12/2003WO2003047524A3 Methods and compositions for modulating the immune system and uses thereof
09/12/2003WO2003037268A3 Hepta-, octa- and nonapeptides having antiangiogenic activity
09/12/2003WO2003034995A3 Integrin targeting compounds
09/12/2003WO2003033027A3 Dendrimers for use in targeted delivery
09/12/2003WO2003032814A3 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
09/12/2003WO2003007794A3 Invasion complex and methods of targeting
09/12/2003WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent
09/12/2003WO2002080966A3 Method for producing a vaccine containing autologous antibodies
09/12/2003WO2002072830A3 Proteins associated with cell growth, differentiation, and death
09/12/2003WO2002070677A3 Palmityl transferases
09/12/2003WO2002058695A9 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
09/12/2003WO2002048370A3 Compositions and methods relating to colon specific genes and proteins
09/12/2003WO2002032961A8 Novel polypeptides and nucleic acids encoding same
09/12/2003WO2002028855A3 Amorphous form of cell cycle inhibitor
09/12/2003WO2002028424A9 Kyberdrug as autovaccines with immune-regulating effects
09/12/2003WO2001095785A3 Modulation of immune response and methods based thereon
09/12/2003WO2001090197A9 Synthetic peptides and uses therefore
09/12/2003WO2001090064A3 COMPOSITION AND METHOD CONTAINING PRODUCTS EXTRACTED FROM COMMIPHORA Sp. FOR PREVENTION AND TREATMENT OF ABNORMAL CELL GROWTH AND PROLIFERATION IN INFLAMMATION, NEOPLASIA AND CARDIOVASCULAR DISEASE
09/12/2003CA2481307A1 Phthalimide carboxylic acid derivatives
09/12/2003CA2478618A1 Isoquinoline derivatives
09/12/2003CA2478528A1 Semicarbazide derivatives and the use thereof as antithrombotics
09/12/2003CA2478424A1 Self emulsifying drug delivery systems for poorly soluble drugs
09/12/2003CA2478145A1 Formulations and methods of using nitric oxide mimetics in cancer treatment
09/12/2003CA2478124A1 Dna demethylase antisense and chemotherapy combination
09/12/2003CA2478106A1 Solidified tissue immunoadjuvant
09/12/2003CA2478050A1 Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
09/12/2003CA2478042A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
09/12/2003CA2478011A1 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003CA2477953A1 Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
09/12/2003CA2477926A1 Crystalline polymorphic form of irinotecan hydrochloride
09/12/2003CA2477874A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
09/12/2003CA2477795A1 Nucleoside 5'-monophosphate mimics and their prodrugs
09/12/2003CA2477785A1 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
09/12/2003CA2477762A1 Peptides for use in antitumor immunotherapy
09/12/2003CA2477715A1 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
09/12/2003CA2477662A1 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
09/12/2003CA2477647A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof
09/12/2003CA2477590A1 Sumo inhibitors
09/12/2003CA2477505A1 Diamino-pyrimidines and their use as angiogenesis inhibitors
09/12/2003CA2477449A1 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003CA2477423A1 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003CA2477422A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells
09/12/2003CA2477411A1 Local production and/or delivery of anti-cancer agents by stromal cell precursors
09/12/2003CA2477406A1 Dna vaccine against proliferating endothelial cells and methods of use thereof
09/12/2003CA2477403A1 Use of epothilones in the treatment of brain diseases associated with proliferative processes
09/12/2003CA2477003A1 Compounds and methods of treating cell proliferative diseases
09/12/2003CA2476724A1 Prevention of recurrence and metastasis of cancer
09/12/2003CA2475370A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
1 ... 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 ... 2211